Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Int. J. Mol. Sci. 2011, 12(9), 5815-5827; doi:10.3390/ijms12095815
Article

Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response

1,* , 1
, 2
, 1
, 1
, 1
, 1
, 1
, 1
, 3
, 3
, 4,5
, 6
, 6
, 5
, 5
, 5
, 5
, 5
, 5
, 5
 and 1
Received: 29 July 2011; in revised form: 29 August 2011 / Accepted: 30 August 2011 / Published: 9 September 2011
(This article belongs to the Special Issue Membrane Transport)
View Full-Text   |   Download PDF [333 KB, updated 19 June 2014; original version uploaded 19 June 2014]
Abstract: Aims: The relationship between variants in SLCO1B1 and SLCO2B1 genes and lipid-lowering response to atorvastatin was investigated. Material and Methods: One-hundred-thirty-six unrelated individuals with hypercholesterolemia were selected and treated with atorvastatin (10 mg/day/4 weeks). They were genotyped with a panel of ancestry informative markers for individual African component of ancestry (ACA) estimation by SNaPshot® and SLCO1B1 (c.388A>G, c.463C>A and c.521T>C) and SLCO2B1 (−71T>C) gene polymorphisms were identified by TaqMan® Real-time PCR. Results: Subjects carrying SLCO1B1 c.388GG genotype exhibited significantly high low-density lipoprotein (LDL) cholesterol reduction relative to c.388AA+c.388AG carriers (41 vs. 37%, p = 0.034). Haplotype analysis revealed that homozygous of SLCO1B1*15 (c.521C and c.388G) variant had similar response to statin relative to heterozygous and non-carriers. A multivariate logistic regression analysis confirmed that c.388GG genotype was associated with higher LDL cholesterol reduction in the study population (OR: 3.2, CI95%:1.3–8.0, p < 0.05). Conclusion: SLCO1B1 c.388A>G polymorphism causes significant increase in atorvastatin response and may be an important marker for predicting efficacy of lipid-lowering therapy.
Keywords: OATP; atorvastatin; single nucleotide polymorphisms; pharmacogenetics OATP; atorvastatin; single nucleotide polymorphisms; pharmacogenetics
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Rodrigues, A.C.; Perin, P.M.S.; Purim, S.G.; Silbiger, V.N.; Genvigir, F.D.V.; Willrich, M.A.V.; Arazi, S.S.; Luchessi, A.D.; Hirata, M.H.; Bernik, M.M.S.; Dorea, E.L.; Santos, C.; Faludi, A.A.; Bertolami, M.C.; Salas, A.; Freire, A.; Lareu, M.V.; Phillips, C.; Porras-Hurtado, L.; Fondevila, M.; Carracedo, A.; Hirata, R.D.C. Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response. Int. J. Mol. Sci. 2011, 12, 5815-5827.

AMA Style

Rodrigues AC, Perin PMS, Purim SG, Silbiger VN, Genvigir FDV, Willrich MAV, Arazi SS, Luchessi AD, Hirata MH, Bernik MMS, Dorea EL, Santos C, Faludi AA, Bertolami MC, Salas A, Freire A, Lareu MV, Phillips C, Porras-Hurtado L, Fondevila M, Carracedo A, Hirata RDC. Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response. International Journal of Molecular Sciences. 2011; 12(9):5815-5827.

Chicago/Turabian Style

Rodrigues, Alice C.; Perin, Paula M. S.; Purim, Sheila G.; Silbiger, Vivian N.; Genvigir, Fabiana D. V.; Willrich, Maria Alice V.; Arazi, Simone S.; Luchessi, Andre D.; Hirata, Mario H.; Bernik, Marcia M. S.; Dorea, Egidio L.; Santos, Carla; Faludi, Andre A.; Bertolami, Marcelo C.; Salas, Antonio; Freire, Ana; Lareu, Maria V.; Phillips, Christopher; Porras-Hurtado, Liliana; Fondevila, Manuel; Carracedo, Angel; Hirata, Rosario D. C. 2011. "Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response." Int. J. Mol. Sci. 12, no. 9: 5815-5827.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert